As an accomplished business executive and 25-year veteran of the biotech sector, Dr. Alan Hauser is leveraging his cross-functional leadership experience to create shareholder value for a UC Irvine spatialomics spinout, Arvetas Biosciences. To cross the chasm from multi-omics innovation to profitability in the marketplace, Alan applies his past success encompassing the technical, intellectual property, marketing, corporate development, and operational aspects of commercializing emerging drug-discovery and diagnostics platforms. With a goal of improving people’s lives, his work directed toward planning, promoting, prospecting, appraising plus ROI-led partnering have contributed to launching 9 genomic products, completing > 65 strategic or revenue-generating alliances, and building 9 biotool businesses, including a Silicon Valley startup’s $189 million IPO. Since obtaining his doctorate in chemical and biomolecular engineering at UC Berkeley, Alan completed the executive program at Northwestern’s Kellogg Management Institute as well as additional finance courses at the University of Chicago and Harvard.
Clinical Dx Showcase:
The Arvetas BioSciences single-scan imaging platform, unlike other spatialomic technologies, interrogates the tumor microenvironment of tissue biopsies via RNA/protein detection, so our solution cost-effectively scales as a translational-research and diagnostic tool to enable precision cancer care.
Spatialomics Solution for Disrupting Discovery and Diagnostics
Arvetas BioSciences is addressing significant unmet scientific and medical needs with our multiplexed molecular-marker imaging platform. The single-scan staining solution enables our disparate discovery and diagnostics customers to achieve high-plex spatial transcriptomic and proteomic profiling in an unprecedentedly cost-effective manner.
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative